| COVID-19 vaccination and breakthrough infections in patients with cancer AL Schmidt, C Labaki, CY Hsu, Z Bakouny, N Balanchivadze, SA Berg, ... Annals of oncology 33 (3), 340-346, 2022 | 90 | 2022 |
| Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the … Z Bakouny, T El Zarif, S Dudani, JC Wells, CL Gan, F Donskov, J Shapiro, ... European urology 83 (2), 145-151, 2023 | 58 | 2023 |
| Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors AH Nassar, E Adib, S Abou Alaiwi, T El Zarif, S Groha, EW Akl, PV Nuzzo, ... Cancer Cell 40 (10), 1161-1172. e5, 2022 | 55 | 2022 |
| Germline variants associated with toxicity to immune checkpoint blockade S Groha, SA Alaiwi, W Xu, V Naranbhai, AH Nassar, Z Bakouny, T El Zarif, ... Nature medicine 28 (12), 2584-2591, 2022 | 48 | 2022 |
| Drug repurposing towards targeting cancer stem cells in pediatric brain tumors HF Bahmad, MK Elajami, T El Zarif, J Bou-Gharios, T Abou-Antoun, ... Cancer and Metastasis Reviews 39 (1), 127-148, 2020 | 37 | 2020 |
| CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer E Adib, T El Zarif, AH Nassar, EW Akl, S Abou Alaiwi, TH Mouhieddine, ... British journal of cancer 126 (5), 797-803, 2022 | 26 | 2022 |
| The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response JE Berchuck, E Adib, S Abou Alaiwi, AK Dash, JN Shin, D Lowder, ... Cancer research 82 (16), 2848-2859, 2022 | 21 | 2022 |
| Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study Z Bakouny, C Labaki, S Bhalla, AL Schmidt, JA Steinharter, J Cocco, ... Annals of Oncology 33 (8), 836-844, 2022 | 21 | 2022 |
| Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing T El Zarif, M Yibirin, D Oliveira-Gomes, M Machaalani, R Nawfal, G Bittar, ... Cancers 14 (9), 2105, 2022 | 18 | 2022 |
| Measles and mumps outbreaks in Lebanon: trends and links T El Zarif, MF Kassir, N Bizri, G Kassir, U Musharrafieh, AR Bizri BMC Infectious Diseases 20, 1-10, 2020 | 16 | 2020 |
| Liquid biopsy epigenomic profiling for cancer subtyping SC Baca, JH Seo, MP Davidsohn, B Fortunato, K Semaan, S Sotudian, ... Nature medicine 29 (11), 2737-2741, 2023 | 15 | 2023 |
| Human rabies control in Lebanon: a call for action MF Kassir, T El Zarif, G Kassir, A Berry, U Musharrafieh, AR Bizri Epidemiology & Infection 147, e46, 2019 | 15 | 2019 |
| Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study S Bhalla, Z Bakouny, AL Schmidt, C Labaki, JA Steinharter, DA Tremblay, ... Lung Cancer 160, 78-83, 2021 | 13 | 2021 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 12 | 2023 |
| Epigenomic charting and functional annotation of risk loci in renal cell carcinoma AH Nassar, S Abou Alaiwi, SC Baca, E Adib, RI Corona, JH Seo, ... Nature communications 14 (1), 346, 2023 | 10 | 2023 |
| Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome X Qiu, LG Brown, JL Conner, HM Nguyen, N Boufaied, S Abou Alaiwi, ... JCI insight 7 (10), 2022 | 10 | 2022 |
| Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors T El Zarif, AH Nassar, GR Pond, TZ Zhuang, V Master, B Nazha, S Niglio, ... JNCI: Journal of the National Cancer Institute 115 (12), 1605-1615, 2023 | 8 | 2023 |
| Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma RM Saliby, T El Zarif, Z Bakouny, V Shah, W Xie, R Flippot, T Denize, ... Cancer Immunology Research 11 (8), 1114-1124, 2023 | 7 | 2023 |
| FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma E Adib, T El‐Zarif, RK Jain, WP Skelton IV, D Freeman, C Curran, EW Akl, ... BJUI compass 3 (2), 169, 2022 | 7 | 2022 |
| Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance D Gjuka, E Adib, K Garrison, J Chen, Y Zhang, W Li, D Boutz, C Lamb, ... Cancer cell 41 (10), 1774-1787. e9, 2023 | 6 | 2023 |
